NCT01685827View on ClinicalTrials.gov

Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 11, 2016

Study Completion Date

April 26, 2017

Conditions
Human African Trypanosomiasis (HAT)Sleeping Sickness
Interventions
DRUG

Fexinidazole

DRUG

Nifurtimox

DRUG

Eflornithine

Trial Locations (10)

Unknown

Batangafo, Batangafo

Bagata Hospital, Bagata

Masi Manimba Hospital, Masi Manimba

Vanga Hospital, Vanga

HGR (General Reference Hospital) Bandundu, Bandundu

HGR Mushie hospital, Mushie

CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital, Mbuji Mayi

HS Katanda hospital, Katanda

HGR ISANGI hospital, Isangi

Dingila, Dingila

All Listed Sponsors
lead

Drugs for Neglected Diseases

OTHER

NCT01685827 - Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 | Biotech Hunter | Biotech Hunter